QuickView for Trazodone (compound)

Summary
General Info

PubChem

PubChem Compound 5533

Name:	Trazodone
PubChem Compound ID:	5533
Description:	A serotonin uptake inhibitor that is used as an antidepressive agent. It has been shown to be effective in patients with major depressive disorders and other subsets of depressive disorders. It is generally more useful in depressive disorders associated with insomnia and anxiety. This drug does not aggravate psychotic symptoms in patients with schizophrenia or schizoaffective disorders. (From AMA Drug Evaluations Annual, 1994, p309)
Molecular formula:	C₁₉H₂₂ClN₅O
Molecular weight:	371.864 g/mol
Synonyms:	NINDS_000196; 19794-93-5; Desirel; Beneficat; Trazodone; 1,2,4-Triazolo(4,3-a)pyridin-3(2H)-one, 2-(3-(4-(3-chlorophenyl)-1-piperazinyl)propyl)-; S-Triazolo[4, 3-a]pyridin-3(2H)-one, 2-[3-[4-(m-chlorophenyl)-1-piperazinyl]propyl]-, monohydrochloride; 1,2,4-Triazolo[4,3-a]pyridin-3(2H)-one, 2-[3-[4-(3-chlorophenyl)-1-piperazinyl]propyl]-; Trazodon; KBio1_000196. show more » NINDS_000196; 19794-93-5; Desirel; Beneficat; Trazodone; 1,2,4-Triazolo(4,3-a)pyridin-3(2H)-one, 2-(3-(4-(3-chlorophenyl)-1-piperazinyl)propyl)-; S-Triazolo[4, 3-a]pyridin-3(2H)-one, 2-[3-[4-(m-chlorophenyl)-1-piperazinyl]propyl]-, monohydrochloride; 1,2,4-Triazolo[4,3-a]pyridin-3(2H)-one, 2-[3-[4-(3-chlorophenyl)-1-piperazinyl]propyl]-; Trazodon; KBio1_000196; Spectrum4_000755; Spectrum_001424; Desyrel(trazodone hcl salt); KBio2_004472; Lopac-T-6154; KBio2_007040; Prestwick0_000292; S-Trizolo[4,3-a]pyridin-3(2H)-one, 2-[3-[4-(3-chlorophenyl)-1-piperazinyl]propyl]-, hydrochloride; Spectrum3_001560; 1,2,4-Triazolo[4,3-a]pyridin-3 (2H)-one, 2-[3-[4-(3-chlorophenyl)-1-piperazinyl]propyl]-, monohydrochloride; Bimaran; Sideril; CAS-25332-39-2; Trazonil; BRN 0628010; 25332-39-2; Spectrum2_000854; KBio2_001904; EINECS 243-317-1; KBioSS_001904; Trazodil; s-Triazolo(4,3-a)pyridin-3(2H)-one, 2-(3-(4-(m-chlorophenyl)-1-piperazinyl)propyl)-; SPBio_000867; C07156; SPBio_002443; NSC292811; DivK1c_000196; Prestwick1_000292; Trazodona [Spanish]; Trazodone hydrochloride; Molipaxin; NCGC00016035-01; NCGC00016035-02; KBioGR_001110; Trazodonum [INN-Latin]; KBio3_002540; Trazalon; Trazodona [INN-Spanish]; 2-[3-[4-(m-Chlorophenyl)-1-piperazinyl]propyl]-s-triazolo[4, 3-a]pyridin-3(2H)-one monohydrochloride; AF-1161; Desyrel; Trazodonum [Latin] show less «

DrugBank

Identification

Name:	Trazodone
Name (isomeric):	DB00656
Drug Type:	small molecule
Description:	A serotonin uptake inhibitor that is used as an antidepressive agent. It has been shown to be effective in patients with major depressive disorders and other subsets of depressive disorders. It is generally more useful in depressive disorders associated with insomnia and anxiety. This drug does not aggravate psychotic symptoms in patients with schizophrenia or schizoaffective disorders. (From AMA Drug Evaluations Annual, 1994, p309)
Synonyms:	Trazodone Hcl; Trazodonum [INN-Latin]; Trazodona [INN-Spanish]; Trazodone Hydrochloride
Brand:	Bimaran, Trazodon, Desirel, Trazolan, Trazonil, Pragmazone, Desyrel Dividose, Trittico, Trazalon, Beneficat, Trialodine, Molipaxin, Thombran, Desyrel, Sideril, Tombran, Trazodil
Category:	Anti-anxiety Agents, Antidepressants, Second-Generation, Antidepressive Agents, Second-Generation, Serotonin Uptake Inhibitors
CAS number:	19794-93-5

Pharmacology

Indication:	For the treatment of depression.
Pharmacology:	Trazodone is an antidepressant and hypnotic chemically unrelated to tricyclic, tetracyclic, or other known antidepressant agents. The mechanism of trazodone's antidepressant action in man is not fully understood. In animals, trazodone selectively inhibits serotonin uptake by brain synaptosomes and potentiates the behavioral changes induced by the s... show more » Trazodone is an antidepressant and hypnotic chemically unrelated to tricyclic, tetracyclic, or other known antidepressant agents. The mechanism of trazodone's antidepressant action in man is not fully understood. In animals, trazodone selectively inhibits serotonin uptake by brain synaptosomes and potentiates the behavioral changes induced by the serotonin precursor, 5-hydroxytryptophan. Cardiac conduction effects of trazodone in the anesthetized dog are qualitatively dissimilar and quantitatively less pronounced than those seen with tricyclic antidepressants. Trazodone is not a monoamine oxidase inhibitor and, unlike amphetamine-type drugs, does not stimulate the central nervous system. In man, trazodone is well absorbed after oral administration without selective localization in any tissue. Since the clearance of trazodone from the body is sufficiently variable, in some patients trazodone may accumulate in the plasma. show less «
Mechanism of Action:	Trazodone binds at 5-HT2 receptor, it acts as a serotonin agonist at high doses and a serotonin antagonist at low doses. Like fluoxetine, trazodone's antidepressant activity likely results from blockage of serotonin reuptake by inhibiting serotonin reuptake pump at the presynaptic neuronal membrane. If used for long time periods, postsynaptic neuro... show more » Trazodone binds at 5-HT2 receptor, it acts as a serotonin agonist at high doses and a serotonin antagonist at low doses. Like fluoxetine, trazodone's antidepressant activity likely results from blockage of serotonin reuptake by inhibiting serotonin reuptake pump at the presynaptic neuronal membrane. If used for long time periods, postsynaptic neuronal receptor binding sites may also be affected. The sedative effect of trazodone is likely the result of alpha-adrenergic blocking action and modest histamine blockade at H1 receptor. It weakly blocks presynaptic alpha2-adrenergic receptors and strongly inhibits postsynaptic alpha1 receptors. Trazodone does not affect the reuptake of norepinephrine or dopamine within the CNS. show less «
Absorption:	Rapidly and almost completely absorbed following oral administration. Food may decrease the rate and extent of absorption.
Protein binding:	89-95% bound to plasma proteins in vitro
Biotransformation:	Undergoes extensive hepatic metabolism via hydroxylation, N-dealkylation, N-oxidation and splitting of the pyridine ring. Cytochrome P450 (CYP) 3A4 catalyzes the formation of the major active metabolite, m-chlorophenylpiperazine (m-CPP). Metabolites may be further conjugated to glucuonic acid or glutathione. CYP2D6 is responsible for 4'-hydroxylation of m-CPP and the formation of at least one glutathione conjugates of m-CPP, a quinone imine-sulhydryl adduct. Oxotriazolopyridinpropionic acid, an inactive metabolite, and its conjugates account for about 20% of the total excreted oral dose. Less than 1% of the oral dose is excreted unchanged. Approximately 70-75% of the dose is eliminated in urine with the remainder being excreted in feces via biliary elimination.
Half Life:	Undergoes biphasic elimination with an initial phase t_{1/2 α} of 3-6 hours and a terminal phase t_{1/2 β} of 5-9 hours.
Toxicity:	LD₅₀=96mg/kg (i.v. in mice)
Affected organisms:	Humans and other mammals

Interactions

Food interaction:

Food decreases the rate and extent of absorption.

Avoid alcohol.

Drug interaction:

Ginkgo biloba	Increased effect and toxicity of both agents
Meperidine	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
Sertraline	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
Trimipramine	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
Lithium	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.

Ginkgo biloba	Increased effect and toxicity of both agents
Meperidine	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
Sertraline	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
Trimipramine	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
Lithium	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
Maprotiline	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
Etravirine	The CYP3A4 inducer, Etravirene, may decrease Trazodone efficacy/toxicity by increasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Etravirine is initiated, discontinued or dose changed.
Tranylcypromine	Increased risk of serotonin syndrome. Use caution during concomitant therapy and monitor for symptoms of serotonin syndrome.
Zolmitriptan	Use of two serotonin modulators, such as zolmitriptan and trazodone, may increase the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy.
Sitaxentan	The CYP3A4 inhibitor, Sitaxsenten, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Norfloxacin is initiated, discontinued or dose changed.
Darunavir	The protease inhibitor, Darunavir, may increase the efficacy/toxicity of Trazodone by inhibiting Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Darunavir is initiated, discontinued or dose changed.
Erythromycin	The CYP3A4 inhibitor, Erythromycin , may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Erythromycin is initiated, discontinued or dose changed.
Dextromethorphan	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
Atazanavir	The protease inhibitor, Atazanavir, may increase the efficacy/toxicity of Trazodone by inhibiting Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Atazanavir is initiated, discontinued or dose changed.
Dexamethasone	The CYP3A4 inducer, Dexamethasone, may decrease Trazodone efficacy by increasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Dexamethasone is initiated, discontinued or dose changed.
Dabigatran etexilate	P-Glycoprotein inducers such as trazodone may decrease the serum concentration of dabigatran etexilate. This combination should be avoided.
Tamsulosin	Trazodone, a CYP2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Trazodone is initiated, discontinued, or dose changed.
Lapatinib	The CYP3A4 inhibitor, Lapatinib, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Lapatinib is initiated, discontinued or dose changed.
Tipranavir	The protease inhibitor, Tipranavir, may increase the efficacy/toxicity of Trazodone by inhibiting Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Tipranavir is initiated, discontinued or dose changed.
Aprepitant	The CYP3A4 inhibitor, Aprepitant, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Aprepitant is initiated, discontinued or dose changed.
Posaconazole	The CYP3A4 inhibitor, Posaconazole, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Consider alternate therapy or monitor for changes in Trazodone efficacy/toxicity if Posaconazole is initiated, discontinued or dose changed.
Galantamine	Possible antagonism of action
Procarbazine	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
Telithromycin	The CYP3A4 inhibitor, Telithromycin, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Consider alternate therapy or monitor for changes in Trazodone efficacy/toxicity if Telithromycin is initiated, discontinued or dose changed.
Carbamazepine	The CYP3A4 inducer, Carbamazepine, may decrease Trazodone efficacy by increasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Carbamazepine is initiated, discontinued or dose changed.
Rizatriptan	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
Citalopram	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
Quinidine	The CYP3A4 inhibitor, Quinidine, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Consider alternate therapy or monitor for changes in Trazodone efficacy/toxicity if Quinidine is initiated, discontinued or dose changed.
Isocarboxazid	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
Pentobarbital	The CYP3A4 inducer, Pentobarbital, may decrease Trazodone efficacy by increasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Pentobarbital is initiated, discontinued or dose changed.
Tetracycline	The CYP3A4 inhibitor, Tetracycline, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Tetracycline is initiated, discontinued or dose changed.
Amiodarone	The CYP3A4 inhibitor, Amiodarone, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Amiodarone is initiated, discontinued or dose changed.
Fosphenytoin	The CYP3A4 inducer, Fosphenytoin, may decrease Trazodone efficacy by increasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Fosphenytoin is initiated, discontinued or dose changed.
Promethazine	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
Ritonavir	The protease inhibitor, Ritonavir, may increase the efficacy/toxicity of Trazodone by inhibiting Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Ritonavir is initiated, discontinued or dose changed.
Ergotamine	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
Miconazole	The CYP3A4 inhibitor, Miconazole, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Consider alternate therapy or monitor for changes in Trazodone efficacy/toxicity if Miconazole is initiated, discontinued or dose changed.
Rifampin	The CYP3A4 inducer, Rifampin, may decrease Trazodone efficacy by increasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Rifampin is initiated, discontinued or dose changed.
Haloperidol	The CYP3A4 inhibitor, Haloperidol, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. The CYP2D6 inhibitor, Trazodone, may increase the efficacy of Haloperidol by decreasing Haloperidol metabolism and clearance. Monitor for changes in Trazodone and Haloperidol efficacy/toxicity if either agent is initiated, discontinued or dose changed.
Mirtazapine	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
Tamoxifen	Trazodone may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Consider alternate therapy.
Nevirapine	The CYP3A4 inducer, Nevirapine, may decrease Trazodone efficacy by increasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Nevirapine is initiated, discontinued or dose changed.
Sumatriptan	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
Fluoxetine	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
Efavirenz	The CYP3A4 inhibitor and inducer, Efavirenz, may alter Trazodone efficacy/toxicity by altering Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Efavirenz is initiated, discontinued or dose changed.
Desipramine	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
Escitalopram	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
Clotrimazole	The CYP3A4 inhibitor, Clotrimazole, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Clotrimazole is initiated, discontinued or dose changed.
Lopinavir	The protease inhibitor, Lopinavir, may increase the efficacy/toxicity of Trazodone by inhibiting Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Lopinavir is initiated, discontinued or dose changed.
Desvenlafaxine	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
Primidone	The CYP3A4 inducer, Primidone, may decrease Trazodone efficacy by increasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Primidone is initiated, discontinued or dose changed.
Voriconazole	Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of trazodone by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of trazodone if voriconazole is initiated, discontinued or dose changed.
Lidocaine	The CYP3A4 inhibitor, Lidocaine, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Lidocaine is initiated, discontinued or dose changed.
Saquinavir	The protease inhibitor, Saquinavir, may increase the efficacy/toxicity of Trazodone by inhibiting Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Saquinavir is initiated, discontinued or dose changed.
Methylergonovine	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
Amoxapine	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
Naratriptan	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
Pergolide	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
Cimetidine	The CYP3A4 inhibitor, Cimetidine, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Cimetidine is initiated, discontinued or dose changed.
Cabergoline	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
Imatinib	The CYP3A4 inhibitor, Imatinib, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Consider alternate therapy or monitor for changes in Trazodone efficacy/toxicity if Imatinib is initiated, discontinued or dose changed.
S-Adenosylmethionine	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
Metronidazole	The CYP3A4 inhibitor, Metronidazole, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Metronidazole is initiated, discontinued or dose changed.
Fluvoxamine	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
Nortriptyline	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
Dihydroergotamine	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
Verapamil	The CYP3A4 inhibitor, Verapamil, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Verapamil is initiated, discontinued or dose changed.
Ergonovine	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
Clomipramine	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
Phenelzine	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
St. John's Wort	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
Conivaptan	The CYP3A4 inhibitor, Conivaptan, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Consider alternate therapy or monitor for changes in Trazodone efficacy/toxicity if Conivaptan is initiated, discontinued or dose changed.
Nelfinavir	The protease inhibitor, Nelfinavir, may increase the efficacy/toxicity of Trazodone by inhibiting Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Nelfinavir is initiated, discontinued or dose changed.
Nicardipine	The CYP3A4 inhibitor, Nicardipine, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Consider alternate therapy or monitor for changes in Trazodone efficacy/toxicity if Nicardipine is initiated, discontinued or dose changed.
Rifabutin	The CYP3A4 inducer, Rifabutin, may decrease Trazodone efficacy by increasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Rifabutin is initiated, discontinued or dose changed.
Clarithromycin	The CYP3A4 inhibitor, Clarithromycin, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Consider alternate therapy or monitor for changes in Trazodone efficacy/toxicity if Clarithromycin is initiated, discontinued or dose changed.
Frovatriptan	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
Ketoconazole	The CYP3A4 inhibitor, Ketoconazole, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Consider alternate therapy or monitor for changes in Trazodone efficacy/toxicity if Ketoconazole is initiated, discontinued or dose changed.
Rasagiline	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
Bosentan	The CYP3A4 inducer, Bosentan, may decrease Trazodone efficacy by increasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Bosentan is initiated, discontinued or dose changed.
Ergoloid mesylate	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
Doxepin	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
Phenobarbital	The CYP3A4 inducer, Phenobarbital, may decrease Trazodone efficacy by increasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Phenobarbital is initiated, discontinued or dose changed.
Rivastigmine	Possible antagonism of action
Sibutramine	Increased risk of serotonin syndrome. Avoid concomitant therapy.
Aminoglutethimide	The CYP3A4 inducer, Aminoglutethimide, may decrease Trazodone efficacy by increasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Aminoglutethimide is initiated, discontinued or dose changed.
Selegiline	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
Diltiazem	The CYP3A4 inhibitor, Diltizem, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Diltiazem is initiated, discontinued or dose changed.
Buspirone	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
Oxcarbazepine	The CYP3A4 inducer, Oxcarbazepine, may decrease Trazodone efficacy by increasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Oxcarbazepine is initiated, discontinued or dose changed.
Fosamprenavir	The protease inhibitor, Fosamprenavir, may increase the efficacy/toxicity of Trazodone by inhibiting Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Fosamprenavir is initiated, discontinued or dose changed.
Almotriptan	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
Delavirdine	The CYP3A4 inhibitor, Delavirdine, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Consider alternate therapy or monitor for changes in Trazodone efficacy/toxicity if Delavirdine is initiated, discontinued or dose changed.
Indinavir	The protease inhibitor, Indinavir, may increase the efficacy/toxicity of Trazodone by inhibiting Trazodone metabolism via CYP3A4. Monitor for changes in Trazodone efficacy/toxicity if Indinavir is initiated, discontinued or dose changed.
Duloxetine	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
Eletriptan	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
Venlafaxine	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
Tramadol	The use of two serotonin modulators, such as trazodone and tramadol, may increase the risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
Moclobemide	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
Donepezil	Possible antagonism of action
Fluconazole	The CYP3A4 inhibitor, Fluconazole, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Fluconazole is initiated, discontinued or dose changed.
Cyclosporine	The CYP3A4 inhibitor, Cyclosporine, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Cyclosporine is initiated, discontinued or dose changed.
Bromocriptine	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
Furazolidone	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
Protriptyline	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
Nafcillin	The CYP3A4 inducer, Nafcillin, may decrease Trazodone efficacy by increasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Nafcillin is initiated, discontinued or dose changed.
Rifapentine	The CYP3A4 inducer, Rifapentine, may decrease Trazodone efficacy by increasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Rifapentine is initiated, discontinued or dose changed.
Imipramine	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
Isoniazid	The CYP3A4 inhibitor, Isoniazid, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Consider alternate therapy or monitor for changes in Trazodone efficacy/toxicity if Isoniazid is initiated, discontinued or dose changed.
Nefazodone	Increased risk of serotonin syndrome. The CYP3A4 inhibitor, Nefazodone, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Consider alternate therapy or monitor for symtpoms of sertonin syndrome and changes in Trazodone efficacy/toxicity if Nefazodone is initiated, discontinued or dose changed.
Paroxetine	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
Triprolidine	The CNS depressants, Triprolidine and Trazodone, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
Itraconazole	The CYP3A4 inhibitor, Itraconazole, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Consider alternate therapy or monitor for changes in Trazodone efficacy/toxicity if Itraconazole is initiated, discontinued or dose changed.
Amprenavir	The protease inhibitor, Amprenavir, may increase the efficacy/toxicity of Trazodone by inhibiting Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Amprenavir is initiated, discontinued or dose changed.
Amitriptyline	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
Norfloxacin	The CYP3A4 inhibitor, Norfloxacin, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Norfloxacin is initiated, discontinued or dose changed.
Linezolid	Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
Phenytoin	The CYP3A4 inducer, Phenytoin, may decrease Trazodone efficacy by increasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Phenytoin is initiated, discontinued or dose changed.

show less «

Targets

5-hydroxytryptamine 2A receptor

5-hydroxytryptamine 2C receptor

Sodium-dependent serotonin transporter

5-hydroxytryptamine 1A receptor

Histamine H1 receptor

Alpha-1A adrenergic receptor

Alpha-2A adrenergic receptor

Enzymes

Transporters

Multidrug resistance protein 1

Carriers

Alpha-1-acid glycoprotein 1